CGH (@AGA_CGH) header
CGH (@AGA_CGH) profile picture

Clinical Gastroenterology and Hepatology (CGH) is the official clinical practice journal of the @AmerGastroAssn. Impact Factor: 16.2

Bethesda, MD
Joined March 2017
Photo by CGH (@AGA_CGH)Photo by CGH (@AGA_CGH)Photo by CGH (@AGA_CGH)Photo by CGH (@AGA_CGH)Photo by CGH (@AGA_CGH)Photo by CGH (@AGA_CGH)Photo by CGH (@AGA_CGH)Photo by CGH (@AGA_CGH)Photo by CGH (@AGA_CGH)Photo by CGH (@AGA_CGH)
Pinned Tweet
CGH has received a 2025 Impact Factor of 16.2! On behalf of Editor-in-Chief Charles Kahi, thank you to our editors, authors, reviewers, and readers for your continued support. ow.ly/3tIA50Zeox4 #GITwitter #LiverTwitter @JosephHabibi_MD @AmerGastroAssn
4
15
2,070
📢 AGA is seeking its next Editor-in-Chief of Clinical Gastroenterology and Hepatology (CGH). 5️⃣ five-year term begins July 1, 2028. Applications are due Jan. 15, 2027. 🔗ow.ly/uQ3B51068h5 #GI #Hepatology
2
745
In a large, diverse, contemporary cohort of US adults newly diagnosed with IBD, there has been significant increase in early use of advanced therapies and decline in excess use of corticosteroids. 🔗: ow.ly/35j95105uPY
8
1
22
1,564
🗣️The Everest Project, a nationwide real-world study in China, demonstrated that peginterferon α-2b enhances HBsAg loss in NA-suppressed chronic hepatitis B patients, with 48-week HBsAg loss rates of 26.4% (FAS; N = 15,896) and 33.8% (PPS; N = 12,260). 🔗:ow.ly/bMzM5105tRI
2
1
473
Episodic heavy drinking is prevalent in MASLD and associated with a 3-fold higher odds of advanced liver fibrosis compared to individuals with MASLD without episodic heavy drinking. Read more here! ⬇️ 🔗: ow.ly/2X5b5101Jrj
7
10
1,138
New research alert! 🚨 Patients with prior ascites who receive secondary prophylaxis after variceal bleeding face significantly worse outcomes. Could TIPS be the game-changer they need? Dive into the latest findings here! ⬇️ 🔗: ow.ly/2OtZ5101J4c
1
455
🤰 What does MASLD mean for pregnancy? The Fatty Liver in Pregnancy (FLIP) study evaluated 1,100+ women, finding 87% with steatosis on imaging met MASLD criteria and identifying novel links with adverse maternal & neonatal outcomes. 🔬 @TatyanaKushner 🔗: ow.ly/VZqy5101Ik0
1
2
6
567
🍂 The November issue of CGH is now available! Featured articles: 🔸A study on heavy drinking and Implications for SLD 🔸Research on the Long-Term Effectiveness of Dupilumab in EoE 🔸The influence of SLD and subtypes on pregnancy and neonatal outcomes. 🔗: ow.ly/kwTP5100wVL
1
1
629
Microscopic Colitis is on the rise in 🇸🇪. Prevalence: 170/100k (2021). Lifetime risk: 1/54 women, 1/133 men. MC incidence outpaced normal mucosa, suggesting more biopsies alone don’t explain the increase. 🔗: ow.ly/19L450ZXL1s
2
3
499
💊Long-term data from 6 UC & Crohn’s disease trials show upadacitinib was generally well tolerated, with findings supporting its favorable safety profile and treatment decisions for patients with IBD. 🔗: ow.ly/GB8350ZVruw
485
⏱️ Could earlier treatment make a difference in ulcerative colitis? Starting biologic therapy within 1 year of diagnosis was associated with a lower risk of structural disease progression, supporting earlier treatment. 🩺🔬 🔗: ow.ly/kuMJ50ZVrfe
3
2
12
1,665
📣The THCC-RI accurately stratifies patients with #cirrhosis by their future risk of HCC, offering a powerful tool to guide precision surveillance and early detection. 🔗: ow.ly/rbJs50ZTcto
1
1
641
#MASLD patients with high cardiovascular risk have more severe #liverfibrosis and higher risk of liver complications, highlighting the need for integrated cardiometabolic and hepatic care. 🔗: ow.ly/yFrq50ZTbXY
3
7
1,002
💫 #MetALD affects women differently. From greater alcohol sensitivity to menopause-related risk and transplant disparities, this review synthesizes evidence on sex-specific biology, outcomes, and care gaps in women with MetALD. 🔗: ow.ly/sm6N50ZTbQN
1
582
📖 The October issue of CGH is now online! It features: 🟢A Narrative review on metabolic dysfunction and alcohol-associated steatotic liver disease in women. 🟢Risk Stratification of a Novel Noninvasive Fibrosis Score in MASLD 🟢And much more! 🔗: ow.ly/T2Oo50ZQzfC
1
1
662
⏰Not too late to explore the September issue! If you haven't checked it out yet, don't miss: 🟧Research on IBD and functional dyspepsia in night shift workers 🟧 A systematic review of steroid therapies for eosinophilic esophagitis 🟧 And much more! 🔗: ow.ly/h9v050ZOlMw
1
1
690
#CGH4ALL @AGA_CGH 📣 🚨 A case of Syphilis mimicking Ulcerative Colitis 🔎 22-year-old man with rash & hematochezia 🧫 Colonoscopy appearing like UC + clinical context suspicious -> check for syphilis 🔗 doi.org/10.1016/j.cgh.2025.0… Reported by @MSohaibMD @MishaGautam55 @drradhikasharma @marjan_haider @ZSobaniMD @GutMD_ @ahmed_alqady_md @DrHSKalsi @SMB0019 @Ayaakhras_ @RagurajC
10
17
1,808
This #PeerReviewWeek 💫 CGH recognizes Dr. Joan Genescà as one of our top reviewers! His dedication to peer review has helped ensure scientific quality while advancing clinical practice and medical knowledge. Thank you Dr. Genescà!
1
1
591
📖 It’s #PeerReviewWeek! We're celebrating all the reviewers dedicated to helping AGA publish quality research. 🥳 Watch for journal posts this week as we recognize their impact and reflect on the theme of volume, speed, and quality. 🧠 Learn more: ow.ly/WJct50ZNnS0
7
3
1,247
🩺📈 In a large #MASLD cohort, 1-year changes in liver stiffness predicted long-term liver-related events and decompensation, while CAP, ALT, and FIB-4 changes did not. Early LSM changes may be a strong marker of long-term prognosis. 🔗 ow.ly/sF8N50ZLeJx
1
5
9
1,290
📣Maintaining or improving healthy behaviors during early adulthood was associated with a reduction risk of midlife steatotic liver disease, regardless of genetic background. 🔗: ow.ly/lTML50ZLezK
2
2
619